Why Plug Power Stock Is Powering Down This Week
Plug Power stock popped last week, but it has been trending lower over the past few days.
Investors may be more interested in Bloom Energy after its deal with Oracle than in Plug Power at this point.
Because of its concerning financials, Plug Power isn't a buy now despite the recent drop in its stock price.
10 stocks we like better than Plug Power ›
Climbing 10.5% last week, Plug Power (NASDAQ: PLUG) stock showed some pep in the middle of July. This week, however, the hydrogen and fuel cell stock isn't extending the gain. Although the company didn't have any news to report that would substantiate the decline, investors have, nonetheless, chosen to distance themselves from Plug stock.
According to data provided by S&P Global Market Intelligence, Plug Power stock has dropped 18.5% from the end of last Friday's trading session through the market's close on Thursday.
Putting Plug's plunge in perspective
There are a couple of reasons behind the drop in Plug stock this week. For one, Plug stock has had a pretty rough go of it in 2025. Through the first six months of 2025, shares had dropped 30%. With investors clicking the buy button last week due to a bullish report on the fuel cell industry's prospects, investors may have felt that this week is a good time to cut their losses -- or even collect some profits -- from the otherwise beleaguered stock.
Another source of discomfort for Plug investors this week could stem from a peer. Bloom Energy (NYSE: BE) reported a notable deal with Oracle to deploy fuel cells in support of powering data centers. The same can't be said for Plug Power, so investors looking for fuel cell exposure may be jumping ship with Plug in favor of Bloom Energy.
Does the recent drop in Plug stock provide a buying opportunity?
While Plug stock is a little less expensive now, it doesn't mask the fact that there are ample concerns regarding the company's financials. Therefore, investors should look elsewhere for a hydrogen investment.
Should you invest $1,000 in Plug Power right now?
Before you buy stock in Plug Power, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Plug Power wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!*
Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
6 minutes ago
- Toronto Star
XORTX Completes USD $114,500 Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the closing of its previously announced non-brokered private placement of units ('Units'), whereby it issued 156,849 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$114,500 (the 'Offering'). Under the Offering, each Unit consisted of one common share in the capital of the Company ('Common Share') and one common share purchase warrant ('Warrant'). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of US$1.20 for a period of sixty (60) months following the date of issuance provided, however, that if the closing price of the Common Shares on the Nasdaq is greater than US$2.00 for ten (10) or more consecutive trading days, the Warrants will be accelerated and will expire on the 30th business day following the date of such notice. Closing of the Offering was conditionally approved by the TSX Venture Exchange ('TSXV'), and the securities issued under the Offering are subject to a four-month and one-day statutory hold period. The Company intends to use the proceeds of the Offering for gout programs, general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. ARTICLE CONTINUES BELOW The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any applicable state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. persons,' as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at For more information, please contact: Forward Looking Statements Statements contained in this news release that are not historical facts are 'forward-looking information' or 'forward-looking statements' within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as 'anticipate', 'proposed', 'estimates', 'would', 'expects', 'intends', 'plans', 'may', 'will', and similar expressions, although not all forward-looking information contains these identifying words. More particularly and without limitation, the forward-looking information in this news release includes (i) expectations regarding the Company's current and future financing plans; (ii) expectations concerning the Company's plans and objectives in respect of the Offering's gross proceeds; and (iii) expectations regarding the Company's business plans and operations. Forward-looking information is based on a number of factors and assumptions that have been used to develop such information, but which may prove to be incorrect and are inherently subject to significant business, economic and competitive uncertainties, and contingencies. The material factors and assumptions used in preparing the forward-looking information contained herein include, among others, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and our ability to obtain and maintain intellectual property protection for our product candidates. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the Company's current expectations, assumptions and/or beliefs based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading 'Risk Factors' in XORTX's Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Globe and Mail
6 minutes ago
- Globe and Mail
Amazon Q2 2025 Earnings: Strong Growth Amid Challenges
Inc. ((AMZN)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Amazon's recent earnings call for Q2 2025 paints a picture of robust growth and strategic advancements, despite facing some operational challenges. The overall sentiment was positive, driven by impressive revenue growth and significant improvements in operating income, largely attributed to the success of Prime Day and expansion in AWS and advertising sectors. However, the company is navigating through challenges such as AWS margin declines and supply constraints, which slightly dampen the otherwise optimistic outlook. Strong Revenue Growth Amazon reported a remarkable $167.7 billion in revenue for Q2 2025, marking a 12% increase from the previous year, excluding foreign exchange impacts. This growth underscores Amazon's ability to expand its market presence and capitalize on consumer demand across its diverse business segments. Significant Increase in Operating Income The company achieved an impressive 31% year-over-year increase in operating income, reaching $19.2 billion. This boost reflects Amazon's effective cost management and strategic investments, which have enhanced profitability. Record Prime Day Performance Prime Day 2025 was a standout event, setting new records in sales, items sold, and Prime sign-ups. Independent sellers also experienced their best sales performance, highlighting the event's broad impact across Amazon's ecosystem. AWS Revenue Growth AWS continued its upward trajectory with a 17.5% year-over-year revenue increase, totaling $30.9 billion. This growth reaffirms AWS's position as a critical driver of Amazon's overall financial success. Advertising Revenue Growth Amazon's advertising segment saw a substantial 22% increase in revenue, reaching $15.7 billion. This growth underscores the effectiveness of Amazon's advertising platform and its appeal to marketers. Advancements in Robotics and AI Amazon's deployment of its 1 millionth robot and introduction of AI innovations like DeepFleet have improved operational efficiency by 10%. These advancements highlight Amazon's commitment to leveraging technology for enhanced productivity. Expansion of Same-Day and Next-Day Delivery Amazon plans to extend its same-day and next-day delivery services to over 4,000 U.S. cities by year-end, enhancing customer convenience and competitive advantage. International Segment Profitability The international segment reported an operating income of $1.5 billion, a significant $1.2 billion increase from the previous year, with operating margins improving by 320 basis points to 4.1%. AWS Margin Decline Despite revenue growth, AWS faced a decline in operating margins from 39.5% in Q1 to 32.9% in Q2, attributed to increased stock-based compensation and higher depreciation expenses. Supply Constraints in AWS AWS is experiencing supply constraints, particularly in power and components, which are affecting its capacity to meet demand. This challenge poses a potential risk to future growth if not addressed. Tariff Uncertainty Uncertainty surrounding tariffs, especially in China, continues to pose a risk to costs and demand, adding a layer of complexity to Amazon's global operations. Forward-Looking Guidance Looking ahead, Amazon anticipates net sales between $174 billion and $179.5 billion for Q3 2025, with a favorable foreign exchange impact expected. The company remains focused on cost-effective innovation, enhancing customer experiences, and expanding its AI and cloud services, positioning itself for continued growth. In conclusion, Amazon's Q2 2025 earnings call reflects a positive sentiment, driven by strong financial performance and strategic advancements. While challenges in AWS margins and supply constraints exist, the company's robust growth in key areas and forward-looking strategies suggest a promising outlook for the future.
Globe and Mail
6 minutes ago
- Globe and Mail
DoorDash: A $100 Billion Delivery Giant Under the Microscope
Explore the exciting world of DoorDash (NASDAQ: DASH) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jul. 16, 2025. The video was published on Aug. 8, 2025. Should you invest $1,000 in DoorDash right now? Before you buy stock in DoorDash, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and DoorDash wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Rick Munarriz has no position in any of the stocks mentioned. Travis Hoium has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends DoorDash. The Motley Fool has a disclosure policy.
